By Donna Loyle, communications specialist, LIMR
All clinicians and researchers are welcome to two upcoming seminars hosted by the Lankenau Institute for Medical Research (LIMR) that will explore the potential future use of cannabidiol (CBD) as a therapeutic agent.
CBD is a chemical in the Cannabis sativa plant, also known as marijuana or hemp. More than 80 chemicals, known as cannabinoids, have been identified in the plant. The 2018 U.S. Farm Bill made it legal to sell hemp and hemp products in the United States, which is why CBD is getting more scrutiny in recent months.
William A. Kinney, PhD, chief scientific officer for biopharmaceutical company Kannalife Inc., will give the LIMR seminar “New Cannabidiol-Like Molecules as Pharmaceutical and Cosmetic Ingredients.”
Dr. Kinney’s long career in the pharmaceutical industry included stints at Wyeth and Magainin Pharmaceuticals. At Johnson & Johnson, he pursued drug targets for cardiovascular indications. He invented KLS-13019 for Kannalife Sciences, a company focused on cannabinoid therapeutics. Most recently, Dr. Kinney co-founded Enterin Inc., where he is leading the manufacturing of squalamine phosphate for Parkinson’s disease.
His seminar will be held on Thursday, November 14, from 2 to 3 p.m. in McLean Conference Room in the Annenberg Center at Lankenau Medical Center.
Dynamic Duo talk
The second seminar, a Dynamic Duo session, is entitled “Can Cannabidiol Reduce Peripheral Neuropathy, a Common Difficult Side Effect of Chemotherapy?” Speakers Marisa Weiss, MD, and Melvin Reichman, PhD, will define the hallmarks of the cannabinoid drug class and the endocannabinoid system and discuss potential medical applications and known adverse events.
Dr. Weiss, director of breast radiation oncology at Lankenau Medical Center, is a leading figure in the breast cancer community, having started the education and advocacy website breastcancer.org. She also serves as an adjunct investigator at LIMR. Her present research interests focus on the use of cannabinoid compounds to relieve side effects of breast cancer treatment.
Dr. Reichman is a senior investigator at LIMR and founder and director of the LIMR Chemical Genomics Center where he designed and built a patented automated repository and screening technology to help accelerate drug discovery. Before joining LIMR, he served as a director of drug discovery at major biotechnology firms.
Their Dynamic Duo talk will take place on Tuesday, November 19. Lunch at 11:45 a.m. Talk begins at noon. In Annenberg Center 101 at Lankenau Medical Center.